Literature DB >> 2437563

Effect of a new somatostatin analogue on pancreatic function in healthy volunteers.

E Köhler, C Beglinger, S Dettwiler, I Whitehouse, K Gyr.   

Abstract

We studied the effect of four graded doses of SMS 201-995, a synthetic octapeptide somatostatin analogue (27, 80, 240, and 720 ng/kg/h) on the basal and secretin-plus-cerulein-stimulated exocrine pancreatic function and pancreatic polypeptide (PP) release in five healthy volunteers. Duodenal fluid secretion and bicarbonate output under basal and stimulated conditions were not significantly affected by any dose of SMS. The basal and stimulated enzyme secretion were decreased in a non-dose-dependent manner by all SMS doses used in the study and showed a 75% inhibition of the secretin-plus-cerulein-stimulated trypsin and amylase output. The cerulein-stimulated PP release was significantly suppressed by all four SMS doses. SMS appears to be a strong inhibitor of pancreatic enzyme secretion, at the same time affecting the PP release.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2437563     DOI: 10.1097/00006676-198603000-00008

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  14 in total

1.  Does prophylactic octreotide benefit patients undergoing elective pancreatic resection?

Authors:  C J Yeo
Journal:  J Gastrointest Surg       Date:  1999 May-Jun       Impact factor: 3.452

2.  Effect of octreotide on human sphincter of Oddi motility following liver transplantation.

Authors:  F H Weber; R J Sears; B Kendall; T L Pruett; H A Shaffer; P Yeaton
Journal:  Dig Dis Sci       Date:  1997-06       Impact factor: 3.199

3.  Chronic Use of Long-Acting Somatostatin Analogues (SSAs) and Exocrine Pancreatic Insufficiency (EPI) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Under-recognized Adverse Effect.

Authors:  Muhammad Wasif Saif; Alicia Romano; Melissa H Smith; Rachana Patel; Valerie Relias
Journal:  Cancer Med J       Date:  2020-04-27

4.  Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial.

Authors:  C J Yeo; J L Cameron; K D Lillemoe; P K Sauter; J Coleman; T A Sohn; K A Campbell; M A Choti
Journal:  Ann Surg       Date:  2000-09       Impact factor: 12.969

5.  Use and perceived effectiveness of non-analgesic medical therapies for chronic pancreatitis in the United States.

Authors:  F Burton; S Alkaade; D Collins; V Muddana; A Slivka; R E Brand; A Gelrud; P A Banks; S Sherman; M A Anderson; J Romagnuolo; C Lawrence; J Baillie; T B Gardner; M D Lewis; S T Amann; J G Lieb; M O'Connell; E D Kennard; D Yadav; D C Whitcomb; C E Forsmark
Journal:  Aliment Pharmacol Ther       Date:  2010-10-29       Impact factor: 8.171

6.  The efficacy of the prophylactic use of octreotide after a pancreaticoduodenectomy.

Authors:  Hyoun Jong Moon; Jin Seok Heo; Seong Ho Choi; Jae Won Joh; Dong Wook Choi; Yong Il Kim
Journal:  Yonsei Med J       Date:  2005-12-31       Impact factor: 2.759

7.  Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis?

Authors:  K F Binmoeller; A G Harris; R Dumas; C Grimaldi; J P Delmont
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

8.  Treatment of pain in chronic pancreatitis by inhibition of pancreatic secretion with octreotide.

Authors:  P Malfertheiner; D Mayer; M Büchler; J E Domínguez-Muñoz; B Schiefer; H Ditschuneit
Journal:  Gut       Date:  1995-03       Impact factor: 23.059

9.  Effect of somatostatin 14 on pure human pancreatic secretion.

Authors:  L Gullo; P Priori; C Scarpignato; F Baldoni; G Mattioli; L Barbara
Journal:  Dig Dis Sci       Date:  1987-10       Impact factor: 3.199

10.  Identification of somatostatin-14 and -28 in rat pancreatic juice by a new HPLC method.

Authors:  M Rünzi; M K Müller; M Schimiczek; J von Schönfeld; H Goebell
Journal:  Int J Pancreatol       Date:  1992-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.